Pruritus Visual Analog Scale (Pruritus VAS)
- Introduced by
- Huskisson EC (VAS methodology); adapted for pruritus in dermatology
- Year
- 1983 (VAS); widely adopted for pruritus 1990s–2000s
- Type
- Self-report
- Family
- symptom-severity
What does it do?
The Pruritus Visual Analog Scale (VAS) is a simple, single-item patient-administered tool measuring itch intensity on a continuous 0–10 (or 0–100) scale.
Adapted from the original VAS for pain, it is one of the most frequently used outcome measures in dermatological research and clinical practice due to its simplicity, brevity, and responsiveness to treatment. Pruritus VAS is essential in trials of antipruritic therapies and in conditions where itching is a primary complaint (atopic dermatitis, psoriasis, pruritus ani, lichen planus).
The intuition behind the method
Itching is subjective and unmeasurable by objective clinical signs alone. A patient may have clinically moderate eczema but unbearable itching, driving quality-of-life burden and treatment urgency. Conversely, another patient with similar clinical severity may have mild itching. Pruritus VAS captures this subjective dimension simply: 'On a scale of 0 to 10, how severe is your itching?' The visual analog format (moving a cursor along a line) is intuitive, language-free, and highly responsive to even small changes in symptom severity, making it ideal for detecting treatment benefit.
History
The visual analog scale (VAS) was developed by Huskisson in 1983 as a simple tool for measuring pain intensity. Its elegance and responsiveness led to rapid adoption for measuring other subjective symptoms, including pruritus. By the 1990s, Pruritus VAS was standard in dermatological research. However, in the 2000s, more detailed itch instruments (5-D Itch Scale, Itch Measure for Atopic Dermatitis) were developed to capture multidimensional aspects of pruritus (duration, direction, distribution, degree, disability). Today, Pruritus VAS remains the most commonly used single itch measure due to its simplicity, but it is increasingly complemented by multidimensional tools in comprehensive clinical trials. Pruritus VAS is endorsed by the International Forum for the Study of Itch and is featured in guidance documents by dermatological societies.
When to use it
Pruritus VAS is appropriate for any patient with skin disease, particularly those with pruritus as a primary or significant symptom (atopic dermatitis, urticaria, lichen planus, primary biliary cholangitis, pruritus ani). It should be used at baseline and at each follow-up visit to track treatment response. Frequent assessment (weekly or bi-weekly) is feasible due to the measure's brevity. Pruritus VAS is especially valuable in telemedicine settings where objective clinical examination is limited. In clinical trials, it is often used as a secondary efficacy endpoint alongside objective severity measures. For patients with chronic itching, repeated VAS assessment can help identify triggers and guide therapy adjustments.
Limitations and considerations
- Subjectivity; entirely patient-reported; vulnerable to recall bias, mood, and day-to-day fluctuation.
- No dimension capture; does not distinguish between itch frequency, duration, or impact; a patient with itching 1 hour daily at intensity 5 vs. 8 hours daily at intensity 5 would report the same VAS at the moment of assessment.
- Anchor ambiguity; interpretation of 'worst possible itching' is variable across individuals; some patients may not use the full 0–10 scale.
- Single-item limitation; vulnerable to measurement error; no internal consistency checks.
- Does not capture quality-of-life impact directly; high VAS may correlate poorly with functioning in some patients.
- Recall period variability; if assessment is of 'current' vs. 'past 7 days' itch, scores may differ substantially.
- Ceiling and floor effects possible in populations with very mild or very severe disease.
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Simplicity; single item, single question, requires no training or clinician input.
- Brevity; administration takes seconds; very low respondent burden.
- Universality; language-free; visual format accessible to illiterate and multilingual populations.
- Responsiveness; sensitive to small changes in itch intensity; responsive to antipruritic treatments.
- Continuity; yields a continuous score (not ordinal categories), enabling fine-grained assessment of change.
- Validated extensively in dermatological and non-dermatological conditions.
- Suitable for frequent assessment; daily or weekly completion is feasible.
- Electronic versions available; compatible with telemedicine, mHealth apps, and electronic health records.
Applications
- Clinical trial primary or secondary endpoint: Efficacy measure in randomized trials of antipruritic therapies, including topical, systemic, and biologic agents; PASI-75 is often paired with pruritus VAS reduction (e.g., ≥3-point improvement) as dual primary outcomes.
- Routine outpatient monitoring: Baseline and periodic (every 2–4 weeks) assessment during active treatment to quantify itch burden and guide therapy escalation, particularly in chronic conditions like urticaria and atopic dermatitis.
- Telemedicine and remote monitoring: Ideal for phone consultations, patient-reported outcome (PRO) apps, and home-based monitoring; single question minimizes technical burden.
- Trigger identification and diary: Patients maintain daily or weekly pruritus VAS logs to identify environmental or behavioral triggers, informing avoidance strategies and therapy timing.
How it works
How it works
The patient is presented with a horizontal or vertical line, typically 10 cm (100 mm) long, labeled at each end. The left end is labeled '0 = No itching' and the right end is labeled '10 = Worst possible itching' (or equivalent). The patient is asked to mark a single point on the line representing their itch intensity at that moment or over a specified recent period (past 24 hours, past 7 days). Modern digital versions use a slider or electronic scale (0–10 or 0–100). Completion takes seconds.
Formula
Present patient with horizontal or vertical line (typically 10 cm or 100 mm long). Label left end 'No itching' (0) and right end 'Worst possible itching' (10 or 100). Ask patient to mark a single point on the line representing current or recent (past 24 hours or past week) severity of pruritus.
Scoring involves measuring the distance from the left end (0) to the patient's marked point in millimeters or using the digital value directly. For a 10-cm paper scale, divide the millimeter measurement by 10 to yield a score of 0–10. For digital 0–100 scales, the score is read directly. Scores are typically rounded to the nearest 0.5 unit (for 0–10) or nearest 1 unit (for 0–100). No calculations or subscales; VAS is a single continuous variable.
Formula
Measure distance from left end (0) to patient's mark, yielding a continuous score from 0–10 or 0–100. Round to nearest 0.5 unit for 0–10 scale or nearest 1 unit for 0–100 scale.
On a 0–10 scale: 0 indicates no itching; 1–3 indicates mild itch (not bothersome); 4–6 indicates moderate itch (interferes with activities or sleep intermittently); 7–9 indicates severe itch (substantial impact on daily function and sleep); 10 indicates unbearable/worst-possible itch. A change of ≥2 points on the 0–10 scale (or ≥20 on the 0–100 scale) is considered clinically significant improvement. Complete itching relief (≤1 on 0–10 scale) is a treatment goal in antipruritic trials.
Formula
0 = no itch; 1–3 = mild; 4–6 = moderate; 7–9 = severe; 10 = unbearable itch. Change of ≥2 points on 0–10 scale (or ≥20 on 0–100 scale) indicates clinically significant change. No fixed thresholds for treatment response; interpret as part of symptom cluster.
Common pitfalls
- Failing to specify recall period clearly; asking 'How severe is your itch?' without specifying 'right now' vs. 'on average this week' will yield inconsistent results.
- Over-interpreting single VAS assessments; itch intensity fluctuates hourly; always assess at consistent times or specify assessment window (e.g., 'morning itch' vs. 'night-time itch').
- Assuming VAS pruritus directly reflects clinical severity; a patient with mild SCORAD may have severe itching, and vice versa. Use both objective and subjective measures together.
- Using paper VAS without proper measurement tools (ruler); small errors in measurement compound across assessments.
- Administering without proper anchoring or instruction; patients may interpret scale differently on repeat visits if instructions vary.
- Confusing pruritus VAS with other itch measures (Numeric Rating Scale, 5-D Itch Scale); they have different psychometric properties.
Frequently asked questions
Should Pruritus VAS be combined with objective severity measures like PASI or EASI?
Yes. Pruritus VAS captures subjective itch burden, while objective measures capture disease extent and sign intensity. They do not correlate perfectly; a patient may have mild objective disease but severe itching. Use both together: objective measures for clinical trial efficacy assessment and pruritus VAS for symptom burden and patient-centered benefit.
What is the MCID for Pruritus VAS?
A change of ≥2 points on the 0–10 scale (or ≥20 on the 0–100 scale) is considered clinically significant improvement. However, in patients with very high baseline itch (8–10), a reduction of ≥3 points may be more meaningful. Always report absolute change and percentage change from baseline for contextualization.
How should I handle variability in daily pruritus scores?
Pruritus naturally fluctuates with time of day, stress, temperature, and activity. To reduce variability, standardize assessment: always measure at the same time of day (e.g., morning before activity, or evening before bed), ask specifically about itch over the past 24 hours or past week (not current moment), and assess at consistent intervals (weekly, bi-weekly). Alternatively, calculate the mean of multiple assessments (e.g., twice weekly) to smooth variability.
Can Pruritus VAS be self-administered at home?
Yes. For paper versions, patients can mark a line at home and bring it to clinic, or photograph it for remote documentation. Digital versions (smartphone apps, web forms) enable real-time submission. Ensure clear written instructions and consistent administration format to minimize error.
Is Pruritus VAS suitable for children?
Yes, from age 4–5 years onward; children can understand and mark a scale representing itch severity. For younger children (under 4), pictorial scales (faces ranging from happy to sad) may be more appropriate. Always verify understanding before administration.
Related methods
Sources
Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587-593.
Open DOI referenceCopied.Huskisson EC. Visual analog scales. In: Melzack R, ed. Pain Measurement and Assessment. New York: Raven Press; 1983:33-37.
Open publication referenceCopied.